Best In Class
Nurosym is pioneering a new class of technology that uses bioelectrical signals targeted to neural circuits of organs, treating disease without surgery or drugs. As a clinically focused company founded on science, Nurosym’s primary focus is developing evidence based noninvasive drug-free neuromodulation.
Nurosym at a Glance
Groundbreaking
First CE-Marked non-invasive vagal neuromodulation system
Innovative Investment
$10M invested in clinical research with patented Nurosym technology
Milestone Achievement
Over 3 million treatment sessions successfully completed
Scientific Validation
More than 30 peer-reviewed clinical study publications on Nurosym
Extensive Collaboration
Collaborating with over 60 world-class research partners
Robust Exploration
Over 60 ongoing clinical trials underway
Nurosym Results from 30+ Clinical Trials
Vagus Nerve Activity
Vagus Nerve Activity
Long-Covid Symptoms
Fatigue, Brain Fog, GI Symptoms, Pain
Fatigue
Sleep
Inflammation
Depression Score
Heart Rate Variability
POTS Tachycardia
Oxidative Stress
Memory
Reading
Macrocirculation
Microcirculation
Results in specific study populations. Individual results may vary.
How does Nurosym Work
The Mechanisms of Nurosym Neuromodulation
Nurosym sends patented electrical impulses to the brain via the Vagus Nerve, which leads to:
61% increase in Vagus Nerve Activity & improved Heart Rate Variability
- Stress
- Depression, Anxiety
- Insomnia
- Athletic recovery
- Ageing & Longevity
The parasympathetic nervous system is the body’s internal relaxation & rest mechanism. HRV is an indicator of Vagus Nerve activity. Improving these parameters of HRV indicates targeted stimulation of the vagus nerve and activation of specific self-repair mechanisms of body & mind.
In a clinical trial, a one-hour session of Nurosym favourably altered all three parameters of Heart Rate Variability (HRV), when compared to a placebo.
Figure (a) shows High Frequency HRV is significantly increased ('p=0.001). Figure (b) shows Low-Frequency HRV is significantly decreased ('P=0.001). Figure (c) shows the ratio of LF to HF is significantly decreased (*p=0.002).
Source
Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Cardiovascular and Translational Research Independent Clinical Study on Nurosym device, published in PLOS ONE
40% improved Fatigue, Brain Fog, Depression & Pain (Long Covid Symptoms)
- Chronic Fatigue Syndrome (ME/CFS)
- Stress & Anxiety
- Depression
- Athletic recovery
- Productivity
- Respiratory conditions
In a study of patients experiencing chronic fatigue symptoms after Covid-19 infection, approximately 40% of the participants showed positive responses to treatment involving Nurosym neuromodulation, as evidenced by improvements in fatigue, brain fog, and widespread pain. Improvement in long COVID symptoms, such as persistent fatigue, brain fog, and respiratory issues, can enhance quality of life and reduced disability.
Source
Clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Advances in Neurology and Neuroscience
61% improvement in Inflammation
- Ageing & Longevity
- Muscle pain
- Chronic pain
- Cardiac Conditions (AF, HF, Hypertension)
- Mental health conditions
- Autoimmune conditions
- Post-viral syndromes (Long-Covid, Lyme Disease)
- IBS & other GI symptoms
Inflammation throughout the body and brain contributes to disease development, progression, ageing, and mental health problems.
In a randomised controlled trial of Nurosym neuromodulation, inflammatory cytokines were significantly lower in the group that received low-level transcutaneous vagus nerve stimulation compared to the sham group at the end of 3 months.
The figure presents the changes in two inflammatory biomarkers - Cytokines: Tumor necrosis factor (TNF)‐α and Interleukin (IL)‐8.
Source
Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Journal of Cardiovascular Pharmacology, Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Nature Reviews Cardiology
48% reduced in fatigue & increased energy
- Chronic Fatigue Syndrome (ME/CFS)
- Productivity
- Social functioning
- Brain Fog
- Sleep quality
- Resilience to stress
- Pain perception reduction
- Long-Covid symptoms
- Anti-ageing & longevity
Nurosym neuromodulation has shown a positive effect on fatigue by modulating the autonomic nervous system, contributing to improved energy levels and reduced feelings of exhaustion.
In the study, patients reported sustained improvement even one week after discontinuing the treatment, highlighting the potential of Nurosym for lasting relief from fatigue-related issues.
Source
Clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Advances in Neurology and Neuroscience
45% improvement in depression score & improved mood
- Memory & cognitive enhancement
- Productivity
- Brain Fog
- Alzheimer’s & Dementia
- Social functioning
- Long-Covid
Nurosym neuromodulation decreased depression score & improved mood in only 5 days of treatment.
The Parasym study revealed that a ten-day treatment regimen of Nurosym led to significant improvements in participants, alleviating depression score and brain fog.
Source
Clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Advances in Neurology and Neuroscience
30% improvement in memory and learning
- Chronic Fatigue Syndrome (ME/CFS)
- Long-Covid
- Alzheimer’s & Dementia
- Depression
- Ageing & Longevity
- Cognitive enhancement
Improved memory
Nurosym improves memory on learning tasks in comparison to placebo. (A) There was a significant benefit of Nurosym neuromodulation compared to placebo across all test questions. (B) This effect was driven by a significant benefit of Nurosym neuromodulation on memory questions.
Better learning
Nurosym paired with training improved performance on speed and decoding learning task measures in comparison to placebo. Nurosym neuromodulation significantly improved speed on the Automaticity learning task compared to controls. Nurosym neuromodulation also significantly improved percent correct on the Decoding learning task as compared to controls. ∗p < 0.05.
Source
Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Brain Stimulation
40% reduction in POTS symptoms
- Decreased inflammation
- Improved heart rate & rythm regulation
- Recuded risk of cardiovascular complications
- Post-trauma recovery
- Arrhythmias mitigation
- Oxygen level increase
After two months of using Nurosym therapy, the active group experienced a significant reduction in postural tachycardia syndrome (POTS) compared to the sham group, as observed through heart rate variability analyses. Additionally, the active group showed lower levels of anti-autonomic autoantibodies (specifically α1-AR and β1-AR), indicating a potential improvement in autonomic function and a reduction in inflammation.
Source
Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology. Independently evaluated and funded, published in Journal of the American College of Cardiology
50% improvement in blood vessel flexibility & improved circulation
- Oxygen and nutrient delivery to tissues
- Organ function
- Blood clots risk reduction
- Varicose veins
- Vascular disease risk reduction
- Fatigue
Nurosym has demonstrated the ability to enhance blood circulation compared to a placebo.
This improvement in blood circulation, or perfusion rate, is crucial for efficiently supplying oxygen and nutrients to tissues while removing waste products.
Such enhancements contribute to overall health and longevity by optimizing blood supply to various organs.
Source
Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently funded & evaluated, peer reviewed & published in Journal of Cardiovascular Pharmacology
61% increase in Vagus Nerve Activity & improved Heart Rate Variability
Heart Rate Variability (HRV) is a biomarker of Parasympathetic “rest and digest” system activation, indicating a balanced nervous system often associated with increased vagus nerve activity. In clinical trials, a one-hour session of Nurosym favourably altered three key parameters of Heart Rate Variability (HRV), when compared to placebo. These findings indicate an activation of the parasympathetic 'rest and digest' system, coupled with a decrease in the 'fight or flight' response.
Health implications:
- Stress
- Anxiety
- Exercise recovery
- Longevity
- Dysautonomia
Source
Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Cardiovascular and Translational Research Independent Clinical Study on Nurosym device, published in PLOS ONE
Figure (A) shows High Frequency HRV is significantly increased (*p=0.001). Figure (B) shows Low Frequency HRV is significantly decreased (*P=0.001). Figure (C) shows the ratio of LF to HF is significantly decreased (*p=0.002). It suggests a greater shift towards the parasympathetic side during Nurosym neuromodulation, indicating a more pronounced relaxation response.
(Figure A, B, C, D) The autonomic function response, Nurosym Neuromodulation favourably altered all HRV parameters (A: HF, B: RMSSD, C: pRR50, D: SDRR). Better effects were observed in people with a poorer baseline HRV ratio. Memory effect was observed, meaning HRV remains elevated after neuromodulation was stopped.
40% improvement in Long-Covid symptoms (fatigue, brain fog, pain)
In a study of patients experiencing chronic fatigue symptoms after Covid-19 infection, approximately 40% of the participants showed positive responses to treatment involving Nurosym neuromodulation, as evidenced by improvements in fatigue, brain fog, and widespread pain. Improvement in long COVID symptoms, such as persistent fatigue, brain fog, and respiratory issues, can enhance quality of life and reduced disability.
Health implications:
- Chronic Fatigue Syndrome (ME/CFS)
- Stress & Anxiety
- Depression
- Athletic Recovery
- Productivity
- Respiratory conditions
Source
Clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Advances in Neurology and Neuroscience
(Figure A) A very significant improvement was observed after 10 treatment sessions. (D0 vs. D10: p < 0.0001). Reserach evaluated our proprietary neuromodulation on those suffering with Long-COVID symptoms such as Fatigue, cognitive problems, Depression, Pain etc. Treatment starts after baseline measurement at Day 0 (D0), ending on D10, with follow up measurements one week later (D17).
61% improvement in inflammation
Inflammation throughout the body and brain can contribute to diseases development, premature ageing and mental health problems.
Cytokines are the main biomarkers (measures) of inflammation in the body.
In a randomised controlled trial, inflammatory cytokines were significantly lower in the group that received Nurosym neuromodulation compared to the placebo group at the end of 3 months. The study presented the changes in two inflammatory biomarkers: Tumor necrosis factor (TNF)‐α and Interleukin (IL)‐8 after Nurosym therapy.
Health implications:
- Cardiovascular health (AF, HF, Hypertension)
- Anti-ageing & Longevity
- Muscle pain
- Chronic pain
- Mental health conditions
- Autoimmune conditions (e.g. Rheumatoid Arthritis, Crohn’s Disease)
- Post-viral syndromes (Long-Covid, Lyme Disease)
- IBS, GERD & other GI symptoms
Source
Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Journal of Cardiovascular Pharmacology, Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Nature Reviews Cardiology
(Figure A, B) In a three-month study employing the Nurosym device for heart failure patients, notable improvements (*P < 0.05) were noted in inflammatory biomarkers: (A) Tumor Necrosis Factor (TNF)‐α exhibited a ~23% reduction, while (B) Interleukin (IL)‐8 showed a marked ~61.3% reduction. The investigation specifically targeted participants with elevated baseline inflammation levels.
Reduced fatigue & increased energy
Significant improvement in fatigue scores after treatment (D0 vs. D10, p < 0.0001).
Fatigue was measured using the Pichot Fatigue Scale. Participants reported that the improvements in fatigue remained 1 week after stopping the treatment.
Health implications:
Source
Clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Advances in Neurology and Neuroscience
(Figure) In the study fatigue was assessed using of the Pichot fatigue scale scores during treatment (D0: day 0, D5: day 5 and D10: day 10). The results revealed a substantial reduction in fatigue, registering approximately 48% and higly significant improvment (D0 vs. D10, p < 0.0001) after Nurosym neuromodulation treatment. The individual values and the median are shown.
45% improvement in depression score & improved mood
Nurosym neuromodulation decreased depression score & improved mood in only 5 days of treatment.
The Parasym study revealed that a ten-day treatment regimen of Nurosym led to significant improvements in participants, alleviating chronic symptoms of depression and brain fog.
Health implications:
- Memory & cognitive enhancement
- Productivity
- Brain Fog
- Alzheimer’s & Dementia
- Social functioning
- Long-Covid
Source
Clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Advances in Neurology and Neuroscience
(Figure) The figure shows the evolution of the Beck depression scale (D0: day 0, D5: day 5 and D10: day 10). The results showed a noticeable improvement in mood, registering approximately 45% on the Beck Depression Scale. The individual values and the median are shown.
30% improvement in memory & learning
Nurosym research explores enhancements in memory and neuroplasticity. Improved cognitive function is correlated with the parasympathetic nervous system, whereas cognitive decline is associated with the sympathetic nervous system.
Health implications:
- Cognitive enhancement and performance
- Memory function
- Problem-solving skills
- Alzheimer’s & Dementia
- Anti-ageing & Longevity
- Productivity
- Dementia risk reduction
Source
Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently evaluated and funded, published in Brain Stimulation
(Figure A, B) Nurosym improves memory on learning tasks in comparison to placebo. (A) There was a significant benefit of Nurosym neuromodulation compared to placebo across all test questions. (B) This effect was driven by a significant benefit of Nurosym neuromodulation on memory questions.
(Figure) Nurosym neuromodulation paired with training significantly (*p < 0.05) improved speed performence on the Automaticity learning task compared to placebo controls. Nurosym neuromodulation also significantly (∗p < 0.05) improved percent correct on the Decoding learning task as compared to controls.
40% reduction in POTS symptoms
After two months of using Nurosym therapy, the active group experienced a significant reduction in postural tachycardia syndrome (POTS) compared to the sham group, as observed through heart rate variability analyses. Additionally, the active group showed lower levels of anti-autonomic autoantibodies (specifically α1-AR and β1-AR), indicating a potential improvement in autonomic function and a reduction in inflammation.
Health implications:
- Decreased inflammation
- Improved heart rate & rythm regulation
- Recuded risk of cardiovascular complications
- Post-trauma recovery
- Arrhythmias mitigation
- Oxygen level increase
Source
Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology. Independently evaluated and funded, published in Journal of the American College of Cardiology
50% improvement in blood vessel flexibility & improved circulation
Nurosym has demonstrated the ability to enhance blood circulation compared to a placebo. This improvement in blood circulation, or perfusion rate, is crucial for efficiently supplying oxygen and nutrients to tissues while removing waste products. Such enhancements contribute to overall health and longevity by optimizing blood supply to various organs.
Health implications:
- Oxygen and nutrient delivery to tissues
- Organ function
- Blood clots risk reduction
- Vascular disease risk reduction
- Varicose veins
- Fatigue
Source
Randomised, placebo controlled clinical study using Parasym proprietary neuromodulation technology, Independently funded & evaluated, peer reviewed & published in Journal of Cardiovascular Pharmacology
(Figure (A, B, C): (A) Pseudo color images on dorsum of left hand during (1) baseline, (2) occlusion, and (3) Postocclusive reactive hyperemia (PORH) phase. Blue color represents lower, red represents higher perfusion rates. (B, C) Changes in blood perfusion measured over nail bed area, before and after Nurosym neuromodulation (B) and sham (placebo) stimulation (C). Markedly higher perfusion rate was seen after Nurosym neuromodulation
Meet the Doctors
Dr. Elisabetta Burchi, MD, MBA
Translational research lead at ParasymA practicing doctor of psychiatry, Elisabetta has an MBA from INSEAD Business School, and experience in direct patient care, neuroscience research, communication and management. Dr. Burchi is a physician-scientist, working with Parasym in clinical affairs with a track record of publishing in the most important scientific journals such as The Lancet, writing successful grant proposals for the NIH, and leading the production of editorial, clinical, regulatory and promotional material in collaborative multidisciplinary teams. Dr. Burchi has also coordinated clinical trials and implemented a tele-medicine practice which received a certification of excellence among more than 100,000 professionals.